People on the Move: Specialty Pharmaceutical Companies

Dr. Reddy’s Laboratories Ltd. has appointed Marc Kikuchi as CEO, North America Generics. As part of Dr. Reddy’s senior leadership team, he is responsible for the integrated pharma company’s North America Generics business and is based in the Princeton, N.J., office.

Akorn Inc. appointed Douglas S. Boothe as president and CEO. According to management, Boothe brings deep pharma expertise and a proven track record as Akorn looks forward to its next phase as an independent company committed to rebuilding shareholder value. The specialty generic pharma company is engaged in the development, manufacturing, and marketing of multisource and branded pharmaceuticals.

Correvio Pharma Corp. reported that Mark H.N. Corrigan, M.D., a member of the company’s board of directors, was appointed CEO. After a successful six-year tenure as president and CEO, William Hunter, M.D., is transitioning out of his current role by the end of first-quarter 2019. Dr. Hunter will remain a member of the company’s board of directors. Correvio is a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs.

James Dillard was named executive VP and chief scientific officer of Perrigo Company. He joined Perrigo from Altria Group Inc., where he served as senior VP, Research, Development and Sciences, and chief innovation officer. Perrigo is a leading provider of OTC health and wellness solutions.

Todd P. Branning is now senior VP and chief financial officer at Amneal Pharmaceuticals Inc. Branning was senior VP, chief financial officer, for Teva Pharmaceutical’s Global Generic Medicines division. Amneal is an integrated pharma company developing, manufacturing and distributing generic, brand and biosimilar products.

Fabian Raschke will become chief financial officer and a member of the corporate executive board at Grünenthal, assuming leadership of the company’s finance and IT organization. Raschke leads Grünenthal’s Group Controlling. Grünenthal is an entrepreneurial, science-based pharmaceutical company specializing in pain, gout, and inflammation.

Gary H. Slatko was named senior VP, chief medical officer, of Aquestive Therapeutics Inc. His experience includes six years in drug safety regulatory work at the U.S. FDA as a director in the Office of Medication Error Prevention and Risk Management. Aquestive is focused on identifying, developing, and commercializing differentiated products to solve therapeutic problems.

Frank Bringstrup is now VP, Regulatory Affairs, at Calliditas Therapeutics. He was senior global regulatory lead at Novo Nordisk A/S. Andrew Udell has become VP, North America Commercial. He was previously VP of Commercial for North America at Neuroderm Ltd. Calliditas is developing high-quality products for patients with a significant unmet medical need in niche indications.